In context
Etelcalcetide treats secondary hyperparathyroidism in adults with chronic kidney disease receiving haemodialysis under the Parsabiv label. [1]
At a glance
- Type
- Medicine / medicine family
- Regulatory context
- United States: this overview describes the cited product-specific prescribing information. It is not a statement of Thai approval or current commercial availability.
- Evidence
- The cited product label defines a clinical indication and its limits. It does not validate every formulation or use of a related molecule.
Scope of the labelled use
The evidence does not automatically apply to primary hyperparathyroidism or to people with kidney disease who are not receiving haemodialysis. [1]
Formulation and jurisdiction
A medicine label applies to its named formulation and clinical use. Approval of one product does not establish equivalence for compounded preparations or products bought as research materials. [1]
Safety and clinical context
The full prescribing information includes product-specific warnings, contraindications and monitoring requirements. A clinical assessment must consider these alongside other medicines and individual health conditions.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- PARSABIV — US prescribing information dailymed.nlm.nih.gov